tradingkey.logo

tradingkey.logo
怜玢


AxoGen Inc

AXGN
りォッチリストに远加
42.210USD
+0.860+2.08%
終倀 07-31 16:00ET15分遅れの株䟡
2.27B時䟡総額
損倱額盎近12ヶ月PER

詳现情報 AxoGen Inc 䌁業名

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

AxoGen Incの䌁業情報


䌁業コヌドAXGN
䌚瀟名AxoGen Inc
䞊堎日Dec 17, 1986
最高経営責任者「CEO」Dale (Michael Donald)
埓業員数451
蚌刞皮類Ordinary Share
決算期末Dec 17
本瀟所圚地13631 Progress Blvd.
郜垂ALACHUA
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号32615
電話番号13864626817
りェブサむトhttps://www.axogeninc.com/
䌁業コヌドAXGN
䞊堎日Dec 17, 1986
最高経営責任者「CEO」Dale (Michael Donald)

AxoGen Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--

よくある質問

AxoGen Incの䞊䜍5名の株䞻は誰ですか


AxoGen Incの䞊䜍5名の株䞻は以䞋のずおりです。Ms. Lindsey Hartley

AxoGen IncAXGNの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、AxoGen Incの株匏を保有しおいる機関は399瀟あり、保有株匏の総垂堎䟡倀は玄48.71Mで、党䜓の91.60%を占めおいたす。2025Q4ず比范しお、機関の持ち株は3148593.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。